PMID- 21334948
OWN - NLM
STAT- MEDLINE
DCOM- 20110830
LR  - 20200205
IS  - 1778-7254 (Electronic)
IS  - 1297-319X (Linking)
VI  - 78
IP  - 3
DP  - 2011 May
TI  - Paradoxical exacerbation of tuberculosis after TNFalpha antagonist discontinuation: 
      beware of immune reconstitution inflammatory syndrome.
PG  - 312-5
LID - 10.1016/j.jbspin.2011.01.003 [doi]
AB  - Paradoxical worsening of tuberculosis associated with immune reconstitution 
      during antiretroviral therapy in patients with HIV infection is known as the 
      immune reconstitution inflammatory syndrome (IRIS). Here, we report a case of 
      paradoxical worsening of IFN-alpha induced tuberculosis in a patient experiencing 
      reconstitution of pathogen-specific immune responses after discontinuing TNFalpha 
      antagonist therapy. This case serves to alert clinicians that complications such 
      as tuberculosis may worsen after TNFalpha antagonist discontinuation. This situation 
      may paradoxically require readministration of the immunosuppressive drug in some 
      patients.
CI  - Copyright (c) 2011 Societe francaise de rhumatologie. Published by Elsevier SAS. 
      All rights reserved.
FAU - Rivoisy, Claire
AU  - Rivoisy C
AD  - Service de Medecine Interne, Universite Paris 7, Hopital Saint-Louis, AP-HP, 1, 
      avenue Claude-Vellefaux, 75010 Paris, France.
FAU - Amrouche, Lucile
AU  - Amrouche L
FAU - Carcelain, Guislaine
AU  - Carcelain G
FAU - Sereni, Daniel
AU  - Sereni D
FAU - Bourgarit, Anne
AU  - Bourgarit A
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20110222
PL  - France
TA  - Joint Bone Spine
JT  - Joint bone spine
JID - 100938016
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antitubercular Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Aged
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Antitubercular Agents/therapeutic use
MH  - Bronchoalveolar Lavage Fluid/microbiology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*diagnosis/immunology
MH  - Latent Tuberculosis/*diagnosis/drug therapy/immunology
MH  - Mycobacterium tuberculosis/isolation & purification
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Withholding Treatment
EDAT- 2011/02/22 06:00
MHDA- 2011/08/31 06:00
CRDT- 2011/02/22 06:00
PHST- 2010/11/24 00:00 [accepted]
PHST- 2011/02/22 06:00 [entrez]
PHST- 2011/02/22 06:00 [pubmed]
PHST- 2011/08/31 06:00 [medline]
AID - S1297-319X(11)00004-2 [pii]
AID - 10.1016/j.jbspin.2011.01.003 [doi]
PST - ppublish
SO  - Joint Bone Spine. 2011 May;78(3):312-5. doi: 10.1016/j.jbspin.2011.01.003. Epub 
      2011 Feb 22.